Financial PerformanceThe company reported a net loss of $25 million, which is a significant increase from the previous quarter's $18 million loss, largely due to rising research and development expenses.
Product AdministrationAdministration of Uplizna requires screening for Hepatitis B and tuberculosis, as well as premedication before each infusion, which could complicate its use.
Product ConcernsThere are unresolved questions about the long-term safety and effectiveness of Uplizna, particularly regarding the impact of B-cell depletion.